Norwegian version of this page

Affective disorders

We study bipolar disorders and other illnesses of depression using different methods and approaches.

About the group

Our studies focus on psychopharmacology, neurostimulating treatment, sensor technology, registry research, cognitive function, genetics, and brain imaging in bipolar disorders and other illnesses including depression. The research group has a translational focus with the aim of contributing to increased etiological knowledge of pathophysiological processes in affective disorders, mainly through clinical intervention studies.

The group is part of NORMENT and covers the Bergen Bipolar and Depression Research (BBDF) group at Haukeland University Hospital. The group consists of collaborating researchers with joint projects on mood disorders. Partners in the group are Professor dr.med. Ketil J. Ødegaard, Professor dr. med Ole Bernt Fasmer, Professor dr. med Anders Lund, Professor Åsa Hammar, Professor dr. med Jan Øystein Berle, Associate Professor Leif Oltedal, and Associate Professor Ute Kessler.

Selected projects

  • The Pharmacogenomics of Bipolar Disorder study (PGBD): Identification of genes for lithium response in a prospective sample (PI: Ketil J. Ødegaard)
  • Monitoring of bipolar disorder using sensor technology (part of  INTROMAT-study) (PI: Ketil J. Ødegaard)
  • Effects of ECT in treatment of depression: a prospective neuroradiological study of acute and longitudinal effects on brain structure and function. (PIs: Ketil J. Ødegaard and Leif Oltedal)
  • Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment (PI: Ute Kessler)
  • The Global ECT-MRI Research Collaboration (GEMRIC): Establishing a multi-site investigation of the neural mechanisms underlying response to electroconvulsive therapy (PI: Leif Oltedal)
  • Actigraphy and heart rate variability in mood disorders (PI: Ole Bernt Fasmer)
  • Prescription database research: Mood disorders and comorbidity (PI: Anders Lund)
  • Blue-blocking glasses as additive treatment for mania: A randomized placebo-controlled trial (PI: Tone Henriksen)
  • Optimizing response to Li treatment through personalized evaluation of individuals with bipolar I disorder: the RLiNK Initiative (EU:Horizon-2020) (PIs: Ketil J. Ødegaard and Ole A. Andreassen)
  • Structural brain changes induced by electroconvulsive therapy (ECT): Can the clinical outcome be explained? Can response to treatment be predicted? (PI: Leif Oltedal)
Published Nov. 13, 2018 10:28 AM - Last modified Aug. 31, 2020 11:18 AM